Indivior (NASDAQ:INDV) Hits New 12-Month High - Time to Buy?

Key Points

• Indivior hit a new 52-week high of $40.27 (last $40.19) during mid-day trading on Wednesday, with about 715,931 shares changing hands and the stock up roughly 2.6%.
• Analyst sentiment is largely bullish: the consensus rating is "Buy" with an average target of $39.33, while some firms have raised targets to $48–$50 and Zacks upgraded to a "strong-buy."
• The company reported quarterly EPS of $0.96 on $317 million in revenue (net margin 19.4%); the stock has a $4.95 billion market cap and P/E of 20.8, though reported return on equity was deeply negative (−219.26%).

Indivior PLC (NASDAQ:INDV - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $40.27 and last traded at $40.1940, with a volume of 715931 shares trading hands. The stock had previously closed at $39.59.

Analysts Set New Price Targets

A number of research firms have issued reports on INDV. Northland Securities set a $50.00 target price on shares of Indivior in a research report on Tuesday, January 20th. HC Wainwright upped their target price on shares of Indivior from $35.00 to $48.00 and gave the company a "buy" rating in a research report on Monday, January 12th. Weiss Ratings cut Indivior from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, March 17th. Finally, Zacks Research upgraded Indivior from a "hold" rating to a "strong-buy" rating in a report on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $39.33.

Indivior Stock Up 2.6%

The stock has a market cap of $4.95 billion, a price-to-earnings ratio of 20.83 and a beta of 0.90. The stock's fifty day moving average is $31.95 and its 200-day moving average is $32.63.

Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. The firm had revenue of $317.00 million during the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. As a group, equities research analysts predict that Indivior PLC will post 3.23 earnings per share for the current fiscal year.

Insider Transactions at Indivior

In other news, Director Stuart A. Kingsley acquired 940 shares of the firm's stock in a transaction that occurred on Friday, March 6th. The stock was purchased at an average price of $31.86 per share, for a total transaction of $29,948.40. Following the completion of the acquisition, the director owned 5,582 shares in the company, valued at $177,842.52. This trade represents a 20.25% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.74% of the company's stock.

Hedge Funds Weigh In On Indivior

Institutional investors and hedge funds have recently modified their holdings of the business. CWM LLC acquired a new position in shares of Indivior in the 3rd quarter valued at approximately $25,000. Quarry LP acquired a new position in shares of Indivior in the 3rd quarter valued at approximately $26,000. Raymond James Financial Inc. acquired a new position in shares of Indivior in the 2nd quarter valued at approximately $26,000. Salomon & Ludwin LLC acquired a new position in shares of Indivior in the 4th quarter valued at approximately $30,000. Finally, Harbor Capital Advisors Inc. grew its position in shares of Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company's stock valued at $37,000 after purchasing an additional 781 shares during the period. 60.33% of the stock is currently owned by institutional investors and hedge funds.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.